The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers

NCT02826044 | Unknown Phase 1

• 1 other identifier: SP2086-114
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and Pharmacokinetics profiles of SP2086 in healthy volunteers.

Conditions

Type 2 Diabetes

Outcome Measures

Primary Outcomes (9)

• The maximum plasma concentration (Cmax) of SP2086

  Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086.

  up to Day 13

• The steady-state plasma concentration (Css) of SP2086

  Css (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086

  up to Day 13

• The maximum plasma concentration (Cmax) of SP2086 acid

  Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086.

  up to Day 13

• The steady-state plasma concentration (Css) of SP2086 acid

  Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086

  up to Day 13

• The maximum urine concentration (Cmax) of SP2086

  Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086

  up to Day 13

• The steady-state urine concentration (Css) of SP2086

  Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086

  up to Day 13

• The maximum urine concentration (Cmax) of SP2086 acid

  Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086

  up to Day 13

• The steady-state urine concentration (Css) of SP2086 acid

  Css (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086

  up to Day 13

• Cumulative excretion of SP2086

  up to Day 13

Secondary Outcomes (1)

• The number of volunteers with adverse events as a measure of safety and tolerability

  up to Day 13

Study Arms (3)

SP2086 50mg

EXPERIMENTAL

there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.

Drug: SP2086

SP2086 100mg

EXPERIMENTAL

there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.

Drug: SP2086

SP2086 200mg

EXPERIMENTAL

there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.

Drug: SP2086

Interventions

SP2086 DRUG

The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.

SP2086 100mg; SP2086 200mg; SP2086 50mg

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• BMI(a measure of a person's weight in relation to height)is between 19 and 26 kg/m2,and the weight is equal or less than 100kg.
• without the history of cardiovascular diseases,liver diseases,kidney diseases,gastrointestinal tract diseases,mental nerve diseases and drug allergy.
• Be willing to accept physical contraception.
• Sign the informed consents voluntarily and ensure to completed the study.

You may not qualify if:

• Known allergy to SP2086 or any of the excipients of the formulation of SP2086;
• ever occured myocardial infarction,acute coronary syndrome, transient ischemic attack.
• the B hepatitis surface antigen or hepatitis C antibody or syphilis antibody or HIV antibody was positive.
• had participated three or more clinical trial in one year or had participated one time clinical medicine in one month of screening.
• have the history of blood donation in 3 months of screening or received the blood transfusion in 1 months of screening.
• have the history of tobacco,alcohol or drug abuse.
• History of or current clinically significant medical illness as determined by the Investigator.

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

the First Hosital of Jilin University

Changchun, Jilin, China

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Central Study Contacts

Yanhua Ding, docter

CONTACT

0431-88782168; dingyanhua2003@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2016
• First Posted: July 7, 2016
• Study Start: July 1, 2016
• Primary Completion: September 1, 2016
• Last Updated: July 7, 2016

Record last verified: 2016-04

Locations

CN (1)